Key Highlights
- The CRUSH rule is a proposal, not final.
- Public comments are due January 19, 2027.
- CMS could extrapolate audit findings from a sample to a broader group.
- Oppenheimer expects legal challenges to the proposal.
Where the rule stands
The Centers for Medicare & Medicaid Services released its proposed "Comprehensive Regulations to Uncover Suspicious Healthcare" rule, known as CRUSH, on Monday, November 16. The proposal is not final. Public comments are due January 19, 2027.
Under the proposal, CMS could take findings from Medicare Advantage risk adjustment data validation audits, which check whether the diagnoses plans submit are supported by medical records, and extrapolate them from a sample to an entire contract. The lookback would start with payment year 2018. CMS estimates the change at about $9 billion per payment year and about $90 billion in total savings over 10 years. The agency's estimate is $90.2 billion recovered from 2027 through 2036.
CMS Administrator Dr. Mehmet Oz framed the proposal as a way to "crush fraud, waste, and abuse."
How the comment process works
Federal agencies typically publish proposed rules and then accept feedback from the public, including companies, trade groups, health care providers, patient advocates and lawmakers. After the comment window closes, the agency reviews the submissions and can issue a final rule, revise the proposal or take more time. There is no fixed date by which CMS must act after January 19, and final rules can differ, sometimes substantially, from the versions first proposed.
That gives the insurance industry a formal channel to argue its case. One analyst said CMS "could choose to make adjustments in the final rule." He also said, "The substantially larger collection estimate reflects broader auditing."
Why the market reacted so sharply
Investors did not wait for the final version. On Wednesday, November 18, the second straight day of selling, Humana (NYSE:HUM) was the worst performer in the S&P 500 and UnitedHealth Group (NYSE:UNH) was the worst stock in the Dow Jones Industrial Average. Elevance Health (NYSE:ELV), Centene (NYSE:CNC), CVS Health (NYSE:CVS), Cigna (NYSE:CI) and Molina Healthcare (NYSE:MOH) also fell. The Dow dropped 561.25 points to 50,198.17, and health care stocks pushed the Blue-Chip index to its session low.
Humana stands out for its exposure: Medicare Advantage accounted for $99.4 billion of its $129.7 billion in 2025 revenue.
The legal backdrop
The proposal revives a 2023 RADV rule that a federal judge in Texas vacated in September 2025, in a case brought by Humana. Oppenheimer expects legal challenges to the new proposal and thinks plans would price the cost into their bids. No court has weighed in on the new version.
The Road From a Draft Rule to a Final Decision
January 19, 2027, is the date circled on calendars. Before then, investors will watch for statements from insurers and industry groups about whether they plan to file comments and what changes they will seek. UnitedHealth is expected to give its 2027 outlook before the end of the year, which could show how management is planning around the proposal. Medicare Advantage bids, which plans submit to CMS for each coming year, are another place where any cost from the rule could show up, given Oppenheimer's view. After the comment window, the timing and content of a final rule, and whether it includes adjustments, will be the next big test for the group.





_11_19_2026_12_40_59_565805.jpg)
Please wait processing your request...